Category Archives: Pharmacogenomics

Washington State University is recruiting two genetics researchers to its Spokane campus to launch a $15 million enterprise that will add 135 pharmaceutical scientists.

It's a bold research and job creation that relies, in part, on leveraging a $1.2 million investment of local tax dollars with federal, state and private funds.

"These are people and projects that can be a real catalyst for Spokane," said Susan Ashe, acting executive director of the Health Sciences & Services Authority of Spokane County.

Called the HSSA, the authority was established several years ago to capture a sliver of the local-option sales taxes collected in the Spokane area to help pay for projects designed to create a thriving research cluster here.

If successful, the projects will turn into either sustained research facilities that create jobs, or they will produce ideas or goods that can be commercialized.

Philip Lazarus, a professor and researcher at Penn State University's College of Medicine, has been offered a position to erect a new academic and research program at WSU, a rare opportunity that WSU is dangling as a recruitment tool along with a generous financial package.

The authority is contributing $500,000 over two years to help bring Lazarus to Spokane and set up his program.

"This is pretty exciting stuff. An opportunity in academic research to really create something with your stamp on it," said Gary Pollack, WSU vice provost for health sciences.

Lazarus would work as WSU's chairman of pharmaceutical sciences at the Spokane campus starting in 2014.

His area of expertise is molecular genetics. Specifically, Lazarus is interested in pharmacogenomics. He would bring his independent, federally funded research with him.

View original post here:
WSU recruits geneticists in new research venture

NEW YORK, March 15, 2012 /PRNewswire/ --Reportlinker.com announces that a new market research report is available in its catalogue:

http://www.reportlinker.com/p0795432/Bioinformatics-Market-Outlook-to-2015.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Genomics

During the past decade, the bioinformatics market has significantly evolved across the globe on back of rising genomics industry. The increasing application of genomics in biotech and pharmaceutical research and development has created a huge commercial market for bioinformatics worldwide. As per our latest research report's estimation, the global bioinformatics market, which reached the mark of around US$ 3 Billion in 2010, will expand at a CAGR of around 25% during 2012-2015 as the declining cost of human genome sequencing and increasing public and private sector investment will give a significant boost to the industry.

According to "Bioinformatics Market Outlook to 2015", the content market that includes specialized and generalized databases was the biggest segment of the global bioinformatics industry in 2010, followed by analysis software & services and IT infrastructure. As per our analysis, the software segment is likely to exhibit strong performance in future, improving its share in the overall market. On the other hand, content/database market will suffer the downturn due to the increasing popularity of innovative analysis software. We have also discussed in the report how the free databases would impact the sales of the paid ones.

Our report analyzed the wide application of bioinformatics in genomics, proteomics and pharmacogenomics. A further in-depth study of the market revealed that genome studies have completely transformed cancer research in the past few years and oncology has become the leading therapeutic area supported by bioinformatics. We also observed that small firms in the field are opting for outsourcing route to expand their presence. The other key trends and drivers pushing the market have also been elaborated in the comprehensive research study.

The market has witnessed the launches of key bioinformatics products and services in various areas, and we have evaluated these on the basis of their companies and countries in our report. The research includes country-level analysis and looks into the recent developments that may impact the industry's future performance in a significant manner. By providing a brief profile of key market players like Accelrys and Affymetrix and evaluating their recent activities in the study, we have presented the industry's competitive landscape. Overall, the report aims at providing an in-depth knowledge about the global bioinformatics market to clients and investors.1. Analyst View2. Research Methodology3. Key Industry Trends and Drivers3.1 Increasing Bioinformatics R&D Efforts by Players3.2 Strategic Collaborations Aimed at Enhancing Innovations3.3 Financial Support by Governments Strengthening Bioinformatics Research3.4 Oncology Research - Leading Therapeutic Area Being Aided by Bioinformatics3.5 Small Firms Enlarging Presence through Bioinformatics Outsourcing3.6 IT and Internet Growth Boosting Usage of Bioinformatics Tools4. Market Overview4.1 By Segment4.1.1 Analysis Software & Services4.1.2 Content/Database4.1.3 IT Infrastructure4.2 By Application4.2.1 Genomics4.2.2 Proteomics4.2.3 Pharmacogenomics5. Prominent Country Profile5.1 US5.2 UK5.3 Japan5.4 India5.5 China5.6 South Korea5.7 Taiwan5.8 Singapore5.9 Australia6. Recently Commercialized Products and Services7. Key Players7.1 Accelrys, Inc.7.2 Affymetrix, Inc.7.3 Compugen Ltd.7.4 IBM Life Sciences7.5 Kinexus

List of Figures:

Figure 4-1: Global - Cost of Genome Sequencing (US$), 1990 to 2015Figure 4-2: Global - Bioinformatics Market (Billion US$), 2010-2015Figure 4-3: Global - Bioinformatics Market by Segment (%), 2010Figure 4-4: Global - Analysis Software & Services Market (Million US$), 2010-2015Figure 4-5: Global - Content Market (Million US$), 2010-2015Figure 4-6: Global - IT Infrastructure Market (Million US$), 2010-2015Figure 4-7: Global - Bioinformatics IT Infrastructure Market by Segment (%), 2010Figure 4-8: Global - DNA Sequencing Market (Billion US$), 2010-2015Figure 4-9: Global - Proteomics Market (Billion US$), 2010-2015Figure 4-10: Global - Pharmacogenomics Market by Segment (%), 2009Figure 5-1: UK - Bioinformatics Market (Million US$), 2010-2015Figure 5-2: India - Bioinformatics Market (Billion INR), 2010-2015Figure 5-3: South Korea - Bioinformatics Market (Million US$), 2010-2015

List of Tables:

Table 4-1: Key Molecular Dynamics SoftwareTable 4-2: Key Molecular Modeling SoftwareTable 4-3: Key Open Source Bioinformatics SoftwareTable 4-4: Types of Generalized DatabasesTable 4-5: Types of Specialized DatabasesTable 4-6: Top Countries for High Content Analysis ResearchTable 4-7: Growth in Key Bioinformatics Databases (Dec 2010 & Dec 2011)Table 4-8: Top Countries for DNA Sequence Analysis ResearchTable 4-9: Key Genome Interpretation Databases and ResourcesTable 4-10: Available Data Sources and Gene Prioritization ToolsTable 4-11: Single Nucleotide Variants Interpretation ToolsTable 4-12: Top Countries for Proteomics ResearchTable 4-13: Mass Spectrometry E-ProgramsTable 4-14: 2-DE E-DatabasesTable 4-15: Key Pharmacogenomic DatabasesTable 4-16: Top Ten PharmGKB Gene, Drug, Disease and Pathway Pages (2009)Table 5-1: Top Countries for Bioinformatics ResearchTable 6-1: Recently Commercialized Bioinformatics ProductsTable 6-2: Recently Commercialized Bioinformatics Services

Read the original here:
Bioinformatics Market Outlook to 2015

By Turna Ray

Amid rising adoption and costs of molecular diagnostics to personalize treatment decisions, insurer UnitedHealthCare is calling for improvements in the medical claims coding system that will enable accurate test utilization tracking.

In a working paper released this week by its Center for Health Reform & Modernization, UnitedHealthcare also advocates payor-supported clinical utility studies to demonstrate that molecular tests are improving patient outcomes and reducing healthcare costs.

"Reimbursement approaches used today, which involve setting an initial rate and subsequent indexing for inflation, may not reflect appropriately the value to the delivery system of a new technology and its continued use," UHC states in the report. "They also may contribute to the rising costs of new and complex tests. New approaches are needed and the working paper discusses some of the options."

In the paper, the insurer reports that its health plan participants racked up nearly $500 million in genetic and molecular diagnostic testing costs in 2010, a 14 percent increase on a per-person basis since 2008. Overall, national spending on genetic tests and molecular diagnostics "may have reached around $5 billion" in 2010 and could reach as high as $25 billion by 2021, according to the report.

The report also includes the results of a survey of consumers and physicians to gauge their attitudes about genetic testing. A poll of more than 1,200 physicians showed that more than 75 percent of doctors identified the cost of tests and reimbursement issues as the most difficult barrier to incorporating genetic tests in their practice.

Given that the US healthcare system is spending more on molecular diagnostics that will likely get more complex with advancing knowledge about the human genome, UHC makes a number of recommendations that could help payors ensure that they are paying for tests that are robustly validated, improve patient outcomes, and ultimately reduce healthcare costs.

"A new coding system could be a foundation for better analytics, evidence development and coverage," UHC states. "Such a system would assign specific codes to individual genetic tests and genetic testing services."

UHC's recommendations come amid a number of ongoing efforts to update the molecular diagnostic coding system.

The American Medical Association has created a two-tier current procedural terminology coding system for single analyte molecular diagnostics that will likely move into use next year. The AMA has also begun issuing Category 1 codes for multi-analyte, algorithm-based assays, such as Vermillion's OVA1 ovarian cancer test (PGx Reporter 3/7/2012).

Read the original here:
With MDx Usage and Costs on the Rise, UnitedHealthCare Urges Reimbursement Reform

DUBLIN--(BUSINESS WIRE)--

Research and Markets (http://www.researchandmarkets.com/research/831b19/stephens_detectio) has announced the addition of John Wiley and Sons Ltd's new book "Stephens' Detection and Evaluation of Adverse Drug Reactions: Principles and Practice (6th Edition)" to their offering.

Written with practitioners in mind, this new edition of Stephen's Detection of Adverse Drug Reactions: Principle and Practice continues to be one of the corner stones of the pharmaceutical medicine list. The classic text covers the issues and problems involved in the detection of adverse drug reactions (ADRs) throughout the life cycle of a medicine from animal studies through to clinical trials, its introduction to the market, followed by wide clinical use, and eventual decline in use or withdrawal. The sixth edition is completely revised and updated including five new chapters on pharmacogenomics, ADRs with herbal medicines, safety of medical devices, safety issues with oncology drugs, and economic aspects of ADRs. All tables and web information needed in order to practice are included to make this sixth edition a complete primer for the new practitioner and a reference for the more experienced.

Key Topics Covered:

Authors:

John Talbot, Senior Lecturer, University of Hertfordshire, UK. Formerly Director, Global Drug Safety, AstraZeneca R&D Charnwood, Loughborough, Leicestershire, UK

Jeffrey Aronson, Reader in Clinical Pharmacology, University of Oxford, Oxford, UK and President Emeritus of the British Pharmacological Society

For more information visit http://www.researchandmarkets.com/research/831b19/stephens_detectio

Continue reading here:
Research and Markets: Stephens' Detection and Evaluation of Adverse Drug Reactions: Principles and Practice (6th ...

March 13, 2012 in City Researchers wooed to organize $15 million researchcenter

The HSSA was established several years ago to capture some of the local-option sales taxes collected in the Spokane area to help pay for projects designed to create a thriving research cluster in thearea.

Washington State University is recruiting two genetics researchers to its Spokane campus to launch a $15 million research enterprise that will add 135 pharmaceuticalscientists.

Its a bold research and job-creation effort announced Monday that relies in part on leveraging a $1.2 million investment of local tax dollars with federal, state and privatefunds.

These are people and projects that can be a real catalyst for Spokane, said Susan Ashe, acting executive director of the Health Sciences & Services Authority of SpokaneCounty.

Called the HSSA, the authority was established several years ago to capture a sliver of the local-option sales taxes collected in the Spokane area to help pay for projects designed to create a thriving research clusterhere.

If successful, the projects will turn into either sustained research facilities that create jobs, or they will produce ideas or goods that can becommercialized.

Philip Lazarus, a professor and researcher at Penn State Universitys College of Medicine, has been offered a position to erect a new academic and research program at WSU, a rare opportunity that WSU is dangling as a recruitment tool along with a generous financial package. The HSSA is contributing $500,000 over two years to help bring Lazarus to Spokane and set up hisprogram.

This is pretty exciting stuff. An opportunity in academic research to really create something with your stamp on it, said Gary Pollack, WSU vice provost for healthsciences.

More:
WSU venturing into pharmacogenomics - Tue, 13 Mar 2012 PST

GIA announces the release of a comprehensive global report on Biochips markets. Global market for Biochips is projected to reach US$4.6 billion by the year 2017. A promising market on the growth curve, Biochips are opening up new avenues for research and science, owing to the trend towards miniaturisation, parallelisation and the high alacrity of analysis. Besides genome analysis, Biochips are increasingly finding use in areas such as protein, diagnostics, toxicological, and biochemical research applications.

San Jose, CA (PRWEB) March 09, 2012

As stated by the new market research report on Biochips, the US continues to remain the largest regional market, with its technological superiority. Segment-wise, DNA Chips constitute the largest market. Despite plummeting market share, the segment is likely to continue its dominance in the biochip products market through 2017. Global Protein Biochips market is set for robust growth driven by anticipated rise in demand from proteomics and gene expression profiling applications. Gene expression profiling is expected to continue as the leading application area for biochips, while pharmacogenomics is expected to register robust growth.

Major players in the marketplace include Affymetrix Inc., Agilent Technologies., Bio-Rad Laboratories Inc., Caliper Life Sciences Inc., Cepheid Inc., Fluidigm Corporation, GE Healthcare Ltd., Illumina, Inc., and Life Technologies Corporation, among others.

The research report titled "Biochips: A Global Strategic Business Report" announced by Global Industry Analysts, Inc., provides a comprehensive review of trends, issues, strategic industry activities, and profiles of major companies worldwide. The report provides market estimates and projections (US$ Million) for the years 2009 through 2017 across global and regional markets for product segments including DNA Chips, Protein Chips, and Lab Chips. Geographic markets analyzed include the US, Canada, Japan, Europe, and Rest of World.

For more details about this comprehensive market research report, please visit

http://www.strategyr.com/Biochips_Market_Report.asp

About Global Industry Analysts, Inc.

Global Industry Analysts, Inc., (GIA) is a leading publisher of off-the-shelf market research. Founded in 1987, the company currently employs over 800 people worldwide. Annually, GIA publishes more than 1300 full-scale research reports and analyzes 40,000+ market and technology trends while monitoring more than 126,000 Companies worldwide. Serving over 9500 clients in 27 countries, GIA is recognized today, as one of the world's largest and reputed market research firms.

Follow us on LinkedIn

Read the original here:
Global Biochips Market to Reach US$4.6 Billion by 2017, According to New Report by Global Industry Analysts, Inc.